Mifepristone mail access temporarily restored as Supreme Court pauses 5th Circuit ruling
Updated
Updated · SCOTUSblog · Apr 29
Mifepristone mail access temporarily restored as Supreme Court pauses 5th Circuit ruling
8 articles · Updated · SCOTUSblog · Apr 29
Justice Samuel Alito’s order directs the FDA and Louisiana to respond by 5 p.m. EDT on 7 May and lasts until 5 p.m. EDT on 11 May.
Drugmakers Danco Laboratories and GenBioPro said the appeals court’s reinstated in-person dispensing rule created immediate confusion for time-sensitive care and regulatory disruption.
The dispute revives a fight over FDA abortion-pill rules after the Supreme Court in 2024 held anti-abortion doctors and medical groups lacked standing to challenge expanded access.
Beyond this single medication, could this legal battle allow other long-approved drugs to be challenged and pulled from shelves?
When a drug's fate is in legal limbo, who should be the final arbiter of medication safety: scientists or judges?
How might the final ruling on mail-order medication reshape the future of telehealth and patient access across the country?
Supreme Court Stay Halts 5th Circuit Ban on Mail Delivery of Mifepristone, Preserving Nationwide Access
Overview
In May 2026, the U.S. Supreme Court temporarily blocked a ruling by the Fifth Circuit that had reinstated a nationwide in-person requirement for obtaining the abortion medication mifepristone. This ruling had disrupted access by ending telehealth prescriptions and mail delivery, forcing some providers to use less effective methods and prompting states to enact laws protecting telehealth abortion services. The legal battle began when Louisiana sued the FDA over its 2023 rule allowing remote access, challenging the state's abortion ban. The Supreme Court's stay restored telehealth access temporarily, providing relief while the Court considers the broader case that will shape the future of abortion medication access and federal regulatory authority.